Corporate Profile
Cardiome is a research-based biopharmaceutical company dedicated to the discovery and development of new therapies that will improve the health of patients around the world.
We have one marketed product, BrinavessTM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.
Recent Financials
| Filing Date | Form | Downloads |
|---|---|---|
| 05/15/2013 | 2013 Q1 - Financial Statements |
 |
| 05/15/2013 | 2013 Q1 - MD&A |
|
| 04/18/2013 | FY2012 - XBRL Filings |
 |
Recent News
Press
13 May, 2013
CARDIOME REPORTS FIRST QUARTER RESULTS
+ Click here for Press Release
Webcast
11 May, 2013
Cardiome To Hold First Quarter 2013 Financial Results Conference Call On May 13, 2013
+ Click here for Press Release
+ Click here for Webcast
Press
10 May, 2013
Cardiome To Present At Bloom Burton & Co. Healthcare Investor Conference
+ Click here for Press Release
Press
9 May, 2013
Cardiome To Hold First Quarter 2013 Financial Results Conference Call On May 13, 2013
+ Click here for Press Release
Press
2 May, 2013
Cardiome Accepts The Transfer Of Sponsorship Of U.S. And Canadian Vernakalant IV And Oral Regulatory Filings From Merck
+ Click here for Press Release
Corporate Presentations
Cardiome Corporate Presentation- May 2013